GLP-1 Weight Loss Drug Side Effects Include Permanent Blindness, Warns FDA
The US Food and Drug Administration (FDA) recently issued a warning against GLP-1 medications, which is used widely to facilitate weight loss.
The FDA warned that the use of the drug may cause sudden blindness and permanent vision loss. The drug administration body clarified that the GLP-1 medications, including Novo Nordisk’s Ozempic and Wegovy, Eli Lilly’s Mounjaro and Zepbound, as well as Sanofi’s Soliqua need information about the potential risk of nonarteritic anterior ischemic optic neuropathy on warning labels.
Read Also: Shocking List Of Mass Murders In Kerala Linked To Drug Abuse In Early 2025
According to the FDA, NAION is a rare condition involving sudden reduction of blood flow to the optic nerve, in turn resulting in acute, painless, decreased vision in one eye, including permanent vision loss. The risk factor of NAION include diabetes, smoking, hypertension, as well as hypercholesterolemia.
Read Also: Use Of AI In Drug Manufacturing, Testing ‘More Accurate And Human Pertinent’: FDA
